Dr Reddys Labs and Cipla are looking attractive at current levels. One can avoid Ranbaxy Labs, says Sudarshan Sukhani of s2analytics.com.
first published: Jun 4, 2013 05:42 pm
A collection of the most-viewed Moneycontrol videos.

Relief Rally in Global Markets 🌍 | Oil Cools, Hormuz Tensions | Nifty 23,500 in Focus | Opening Bell

Iran-US War Update: “No War” Starmer Rejects Iran Conflict, Announces £53M Support Plan

Reliance Foundation Chairperson Nita Ambani Visits KISS to Receive Humanitarian Award

US-Iran War Update: “We Didn’t Start This” Germany Rejects Trump’s Push for Action Against Iran
You are already a Moneycontrol Pro user.


